Technology | Neuro Imaging | March 15, 2018

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform

CereMetrix Silver will feature advanced neuroimaging capabilities that automatically pinpoints and quantifies brain function down to the voxel level.

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform

March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging analytics and quantification platform CereMetrix Silver. Providers will now have access to objective neuroimaging that detects, quantifies and analyzes brain function down to the voxel level.

The CereMetrix Silver image viewer is available to analyze brain imaging, including PET, SPECT, MRI and CT scans. The platform is designed to increase productivity and accuracy by providing reading physicians with significant workflow efficiencies, including automated cluster analysis that allows for quantitative and statistical analysis of SPECT brain scans by comparing to other registered SPECT brain scans. The proprietary workflow also features an automated reporting capabilities.

With CereMetrix Silver, reading physicians can now allow for the localization and definition of brain function and differentiate between hyper (more than average) and hypo (less than average) function in the brain. Within viewports, the reading doctor can process and display the brain image data in traditional two-dimensional formats, while simultaneously displaying pseudo three-dimensional renderings.

“With the current technology, functional brain imaging results are blended across entire anatomical areas, allowing far more subjectivity in the physician’s interpretation and findings,” said Shane Quint, Chief Technology Officer of CereScan. “CereMetrix Silver provides voxel-level measurements to help physicians objectively analyze the imaging, and make faster diagnostic decisions without compromising value-based care.”

CereMetrix Silver is to be used by trained medical professionals as a tool to aid in the evaluation and information management of digital medical images. The neuroimaging platform will also aid in the assessment of qSPECT (quantitative Single-Photon Emission Computed Tomography) brain scans. The brain imaging data, once reconstructed, will be mapped to a common brain template and anatomical map before applying a clustering algorithm to group pixels/voxels of tissue with deviations from average into clusters.

For more information: http://ceremetrix.io

Related Content

Carestream’s X-ray digital tomosynthesis functionality creates three-dimensional datasets from digital radiography (DR) that can be scrolled through similar to computed tomography (CT) imaging. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2020. Digital tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.
News | Digital Radiography (DR) | January 15, 2020
January 15, 2020 — Carestream’s X-ray digital tomosynthesis (DT) functionality, which creates three-dimensional datas
Videos | Advanced Visualization | December 30, 2019
This is a hologram of a fracture from a...
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
Videos | RSNA | December 18, 2019
ITN Editor Dave Fornell and ITN Consulting Editor Greg Freiherr offer a post-game report on the trends and technologi
 CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and medical imaging companies for the first time at the Radiological Society of North America (RSNA) 2019 meeting. With technology platforms that integrate modeled human physiology into immersive, augmented reality environments, CAE Healthcare partners with vendors to deliver risk-free training solutions that meet the needs of physicians and equipment providers. #RSNA19 #RSNA2019
News | Virtual and Augmented Reality | November 27, 2019
November 27, 2019 — CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and m
The Neuroreader software program quantifies brain volume in study participants with TBI

The Neuroreader software program quantifies brain volume in study participants with TBI. Image courtesy of UCLA Health.

News | Clinical Trials | October 29, 2019
October 29, 2019 — A UCLA-led...